Navigation Links
Genzyme Reports Strong First-Quarter Growth
Date:4/23/2008

ed to the fair value of these rights. Excluding

these rights, the fair values of the assets and liabilities of the

joint venture as of March 31, 2008 were not significant.

(2) As of March 31, 2008, Other assets includes $80,100K for the fair

value of the five million shares of Isis Pharmaceuticals, Inc. common

stock that we purchased in February 2008.

GENZYME CORPORATION

RECONCILIATION OF GAAP TO NON-GAAP EARNINGS

For the Three Months Ended March 31, 2008

(Amounts in thousands, except per share data)

Dilution

Due to Premium on

Common Stock Strategic Equity

NON-GAAP Equivalents Investment

Income Statement

Classification:

Total revenues $1,100,061

Cost of products

and services sold $(265,799)

Selling, general and

administrative $(295,497)

Research and development $(180,312) $(69,900)

Amortization of

intangibles $-

Equity in income (loss)

of equity method

investments $188

Minority interest $463

Gains (losses) on

investments in equity

securities $775

Other $(160)

Investment income $14,870

Interest expense $(1,655)

Summary:

Income (loss) before

income taxes $372,934 $- $(69,900)

(Provision for) benefit

from income taxes $(112,039) $- $13,428

Net income (loss) $260,895
'/>"/>

SOURCE Genzyme Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related biology technology :

1. Genzyme to Build New R&D Center in Beijing
2. Genzyme Provides Update on Myozyme(R) Manufacturing
3. Genzyme Withdraws Bioenvisions European Filing of Evoltra(R) in Elderly AML Patients
4. Genzyme Launches Renvela(R) in the U.S. for Dialysis Patients
5. Genzyme and Isis Announce Hart-Scott-Rodino Approval of Collaboration
6. Genzyme and Isis Announce Strategic Alliance Including Exclusive Worldwide License of Mipomersen
7. BioMarin and Genzyme Restructure Aldurazyme 50/50 Joint Venture
8. Genzyme Receives European CE Mark for Single-Treatment Synvisc-One(TM)
9. Genzyme Announces FDA Approval of Thyrogen(R) for Use in Thyroid Cancer Ablation
10. Genzyme Study of Myozyme(R) for Late-Onset Pompe Patients Meets Co-Primary Efficacy Endpoints
11. Genzyme and Sunway to Collaborate on Gene Therapy Program in China
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)...   Decision Resources Group finds that ... are its oral administration, alternative mechanism of action, ... rheumatologists. Otezla was the first oral therapy specifically ... psoriatic arthritis in the United States ... conventional oral treatments including disease-modifying antirheumatic drugs (DMARDs), ...
(Date:7/1/2015)... 2015   Neuraltus Pharmaceuticals, Inc. , a privately-held ... drugs to treat neurodegenerative diseases such as amyotrophic ... G. Miller , M.D., Director of the Forbes Norris ... Medical Center in San Francisco, has been awarded a ... to help fund a Phase 2 clinical study ...
(Date:7/1/2015)... ... July 01, 2015 , ... A newly launched business plan contest ... the barriers to innovation in life sciences R&D. The Pistoia Alliance President’s Startup Challenge ... of US$15,000 and a period of expert mentorship from a senior industry figure drawn ...
(Date:7/1/2015)... STRATFORD, CONNECTICUT (PRWEB) , ... July 01, 2015 ... ... disinfected or sterilized to combat pathogen transmission. CTI’ new Medical Joysticks have ... of medical devices now have an operator control device that will increase healthcare ...
Breaking Biology Technology:Surveyed Rheumatologists Report That Otezla's Oral Administration is its Single Greatest Advantage Over Currently Available Treatment Options 2Surveyed Rheumatologists Report That Otezla's Oral Administration is its Single Greatest Advantage Over Currently Available Treatment Options 3Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 2Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 3Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 4Pistoia Alliance Launches Startup Challenge 2Pistoia Alliance Launches Startup Challenge 3Sanitized Medical Joysticks for a Safer and Healthier Work Environment 2
... ... Biodiesel Refinery, HOUSTON, March 4 ... has satisfied the conditions precedent,and completed its first funding of $10.6 ... one of the world,s leading,financial services providers for alternative energy companies. ...
... Forget About Storage and Focus on Business, NEW ... provider, announces the launch of ExaStore Clustered NAS 2008,designed ... full range of,applications and environments., "Organizations have seen ... considerable burden," says Dr. Arnon Gat, Exanet,President & CEO. ...
... (Nasdaq: PPHM ), a clinical stage biopharmaceutical,company developing ... virus (HCV) infection, today announced that it will release ... 2008 on March 11,2008 at 7:00 a.m. EDT and ... results at 11:30 a.m. EDT on the same day., ...
Cached Biology Technology:Nova Biosource Fuels Announces First Funding Under $41 Million Senior Secured Credit Facility 2Exanet Announces ExaStore 2008 Clustered NAS System 2Peregrine Pharmaceuticals to Announce Third Quarter FY 2008 Financial Results 2
(Date:6/23/2015)... June 23, 2015  Crossmatch™, a leading ... today announced enhanced functionality of its DigitalPersona ... The enhancements build on the native flexibility ... Altus platform and provide expanded mobile credential ... In today,s environment of increasing cyber-attacks and ...
(Date:6/17/2015)... HILDEN, Germany , June 17, 2015 /PRNewswire/ ... Prime Standard: QIA) today launched new Investigator ® STR ... in the United States . The new ... multiple key genomic markers (short tandem repeats or STRs) for ... to evaluate the quality of DNA in each sample, a ...
(Date:6/16/2015)... , June 16, 2015  With the increasing number ... remains a top concern. The recent compromise of ... need for strong authentication within government agencies. ... biometric one-time password (OTP) authenticator, has been submitted for ... 140-2 Level 3 validation for tamper proofing. ...
Breaking Biology News(10 mins):Crossmatch Releases Enhanced DigitalPersona Altus Advanced Authentication Functionality 2QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 2QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 3QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 4QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 5Government Ready Biometric Security Approaching as HYPR Corp. Files FIPS 140-2 Level 3 Validation for Its Proprietary Biometric Token 2Government Ready Biometric Security Approaching as HYPR Corp. Files FIPS 140-2 Level 3 Validation for Its Proprietary Biometric Token 3
... MD (May 18, 2013) The AGA Research Foundation ... into the relationship between the gut microbiota, one of ... and disease. The AGA Research Awards Panel ... from Massachusetts General Hospital and Harvard Medical School, Boston, ...
... ages will celebrate the science and technology of the ... the inaugural Atlanta Science Festival, March 22-29, 2014. With ... schools and universities, the festival will host more than ... across the city. Learn more at http://atlantasciencefestival.org . ...
... Cargo in Efficient and Sustainable Global Logistics Operations) is ... in the efficiency of intermodal loading systems and the ... comprises 29 European organisations with experience in the logistics ... budget totalling 17,000,000 and a duration of three and ...
Cached Biology News:New gut microbiome research to explore red meat -- colorectal cancer pathway 2First Atlanta Science Festival set for 2014 2New logistics services that will cut energy consumption and CO2 emissions 2
... versatile Zymo-Spin I-96 Plate can be used ... for the large-scale (i.e., 96-well) purification of ... construction and unique silica-based matrix make it ... DNA or RNA in = 10 l ...
...
...
...
Biology Products: